High-Risk Prostate Cancer in a Patient with Untreated Prolactinoma and Castrate-Level Testosterone Suppression: A Case Report.

ABSTRACT:

Introduction

Prolactinomas can induce castrate-level testosterone suppression by dysregulating the hypothalamic-pituitary-gonadal axis. While hypogonadism typically confers a reduced risk for prostate cancer (PCa), malignancy can still occur and may arise via nonclassical pathways of carcinogenesis. Special consideration must be given when initiating treatment for patients with concurrent prolactinoma and PCa due to the complex hormonal interplay between prolactin and testosterone.

Case presentation

A man in his 60s was diagnosed with localized high-risk PCa in the setting of castrate-level testosterone suppression mediated by an untreated prolactinoma. Following consistent treatment with a dopamine receptor agonist, testosterone levels normalized. PCa was managed with exter

SUBMITTER: Seibert TA 

PROVIDER: S-EPMC12659437 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature